Connect Biopharma (CNTB)

• Market cap: $98.6M
• 1 day: -5.35%
• 5 days: 4.12%
• 1 month: -14.90%
• 3 months: 135.62%
• 6 months: 109.47%
• Year to date: 46.28%
• 1 year: 73.53%
• 5 years: -90.43%
• 10 years: -90.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Employees: 62

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

54% more capital invested

Capital invested by funds: $1.56M [Q1] → $2.4M (+$844K) [Q2]

31% more funds holding

Funds holding: 13 [Q1] → 17 (+4) [Q2]

0.72% less ownership

Funds ownership: 5.12% [Q1] → 4.4% (-0.72%) [Q2]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 295% upside
• Avg. target: $7 295% upside
• High target: $7 295% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Brandon Folkes

295% upside $7

Buy Reiterated

13 Aug 2025